Tavneos 10 MG capsule 180S
Ended Awarded Last action
- Contract number
- SPE2DR26F5F6D
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,815
Award facts
- Contract value 100% obligated
- $11,815.15 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $11,815.15 to AmerisourceBergen Drug Corp for the supply of TAVNEOS 10 mg capsules (180-count units). The contract, awarded on January 7, 2026, with an ultimate completion date of January 29, 2026, utilizes firm fixed-price pricing with no set-aside designation, indicating the award was made through full and open competition. Performance of this delivery order will occur at the contractor's facility in Conshohocken, Pennsylvania. This task order is issued under AmerisourceBergen Drug Corp's parent company, Cencora, Inc., which holds a significant Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2031, serving as the primary vehicle for pharmaceutical and medical supply procurement to support military healthcare programs globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, has established itself as a critical federal medical procurement vendor through its extensive portfolio of pharmaceutical deliveries to the Defense Logistics Agency and related federal health systems. The company's federal contract activities demonstrate consistent capability in supplying brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions. TAVNEOS (iptacopan) is a complement inhibitor used in the treatment of paroxysmal nocturnal hemoglobinuria, reflecting the specialized nature of medications supplied through this contract vehicle to support advanced therapeutic needs within the military health system.
Quick answers
Who was awarded contract SPE2DR26F5F6D?
SPE2DR26F5F6D was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26F5F6D worth?
The government has obligated $11,815 on SPE2DR26F5F6D.
Is contract SPE2DR26F5F6D an order under another contract?
Yes. SPE2DR26F5F6D is a delivery order under SPE2DR25D3306, an indefinite delivery contract.
Was contract SPE2DR26F5F6D competed?
The extent of competition for SPE2DR26F5F6D was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award